• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Auto-injectors

MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector

July 24, 2026 By Sean Whooley

Mannkind furoscix readyflow product image

MannKind (Nasdaq:MNKD) announced today that it secured $50 million in a private placement and earned a new regulatory nod. In addition to the funding, the company — which also develops inhaled insulin technology — won FDA approval for the Furoscix ReadyFlow auto-injector. MannKind said it entered into a securities purchase agreement in connection with a […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Pharmaceuticals, Regulatory/Compliance, Technology Tagged With: FDA, mannkind

Thermo Fisher, SHL Medical collab on drug delivery device production

March 25, 2026 By Sean Whooley

Thermo Fisher

Thermo Fisher Scientific today announced a strategic collaboration with drug delivery system provider SHL Medical. The collaboration coincides with the expansion of sterile fill-finish and auto-injector final assembly capacity at its Ridgefield, New Jersey site. Together, Thermo Fisher says its investments establish a fully integrated U.S.-based offering across sterile manufacturing, device assembly and commercial packaging […]

Filed Under: Auto-injectors, Business/Financial News, Contract Services, Drug-Device Combinations, Pharmaceuticals Tagged With: SHL Medical, thermofisherscientific

Embecta to acquire auto-injector maker Owen Mumford for up to $199.4M

March 19, 2026 By Sean Whooley

Embecta Owen Mumford Logos

Embecta (Nasdaq:EMBC) announced today that it entered into a definitive agreement to acquire Owen Mumford Holdings Limited. Owen Mumford, a privately held, UK-based company, develops and manufactures medical devices and drug delivery technologies. Embecta, the former BD Diabetes business, agreed to acquire Owen Mumford with an upfront cash payment of approximately $133 million (£100 million). […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Technology, Wall Street Beat Tagged With: embecta, Owen Mumford

BD, Ypsomed to develop new syringe for biologics

January 22, 2026 By Chris Newmarker

This is a BD Neopak image.

BD (NYSE: BDX) and Ypsomed recently announced they will expand their collaboration through the development of a 5.5 ml version of BD’s Neopak XtraFlow glass prefillable syringe. The new BD syringe is presently in development and will undergo comprehensive testing to ensure its compatibility with Ypsomed’s YpsoMate 5.5 autoinjector platform. Syringe samples for feasibility studies […]

Filed Under: Auto-injectors, Featured Tagged With: BD, biologics, Ypsomed

BD to invest $110M to support prefilled syringe production, pharma supply chain

January 13, 2026 By Sean Whooley

BD Neopak XtraFlow glass prefillable syringe (1)

BD (NYSE:BDX) announced today that it invested $110 million to expand its production of prefillable syringes in Columbus, Nebraska. Franklin Lakes, New Jersey-based BD aims to expand prefillable syringe production to accelerate biologic and GLP-1 drug delivery and support pharmaceutical reshoring in the U.S. The investment brings the company’s Neopak glass prefillable syringe production to […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Technology Tagged With: BD, Becton Dickinson

MannKind earns FDA nod for on-body infusor, new autoinjector patents

December 23, 2025 By Sean Whooley

MannKind Furoscix On-Body Infusor (1)

MannKind (Nasdaq:MNKD) announced today that the FDA approved its Furoscix (furosemide) on-body infusor for pediatric patients. The company also received additional IP protection for its investigational Furoscix ReadyFlow autoinjector. ReadyFlow remains under FDA review after the agency accepted a supplemental New Drug Application (sNDA) earlier this month. For the on-body infusor, the FDA approved the […]

Filed Under: Auto-injectors, Drug-Device Combinations, Food & Drug Administration (FDA), Pediatrics, Regulatory/Compliance, Technology Tagged With: mannkind

FDA accepts MannKind sNDA for autoinjector that treats edema

December 2, 2025 By Sean Whooley

MannKind Logo

MannKind (Nasdaq:MNKD) announced that the FDA accepted a supplemental New Drug Application (sNDA) for its Furoscix ReadyFlow autoinjector. The Furoscix ReadyFlow autoinjector (SCP-111) was developed to deliver a subcutaneous furosemide injection as an investigational alternative to the FDA-approved Furoscix on-body infusion device for treating edema in adult patients with chronic heart failure (CHF) or chronic […]

Filed Under: Auto-injectors, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: FDA, mannkind

Ypsomed launches YpsoLoop autoinjector platform designed for circularity

October 23, 2025 By Sean Whooley

Ypsomed YpsoLoop autoinjector (1)

Ypsomed announced that it launched YpsoLoop, its first autoinjector platform designed for circularity. The Swiss drug delivery device maker says the two new 1 mL and 2.25 mL platforms enable material recovery. Their design enables automated disassembly and efficient recycling while offering the convenience of a pre-filled, two-step autoinjector. Ypsomed said the YpsoLoop platform integrates […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Technology Tagged With: Ypsomed

Analysts label Embecta ‘undervalued’ and poised for growth

September 19, 2025 By Sean Whooley

BD Diabetes Spinoff Embecta

BTIG analysts maintain a “Buy” rating for Embecta (Nasdaq:EMBC) after meetings with company officials highlighted plans for growth. Marie Thibault, Sam Eiber and Alexandra Pang hosted Embecta CEO Devdatt Kurdikar and Head of Investor Relations Pravesh Khandelwal this week. Following the in-person and virtual meetings, the analysts maintain confidence in the former BD Diabetes unit’s […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology, Wall Street Beat Tagged With: embecta

Ypsomed gets FDA nod for digital add-on for autoinjectors

September 4, 2025 By Sean Whooley

Ypsomed SmartPilot with YpsoMate autoinjector (1)

Ypsomed announced that the FDA granted 510(k) clearance for SmartPilot, a digital connectivity add-on for its Ypsomate autoinjectors. The device transforms the YpsoMate into a connected system that automatically captures and transmits injection data. Ypsomed said this marks an important step toward digital health solutions that offer deeper insight into therapy use. The digital add-on […]

Filed Under: Auto-injectors, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Technology Tagged With: FDA, Ypsomed

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 34
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS